Literature DB >> 3526101

Cyclosporin A in organ transplantation.

P J Miach.   

Abstract

Cyclosporin A is a novel, powerful immunosuppressive agent. It is a cyclic polypeptide and is one of several metabolites of a number of soil fungi. Its main effect is directed against the helper T lymphocyte. Thus, cyclosporin A represents the first of a new generation of immunosuppressive agents that are capable of selective rather than broad spectrum activity. The immunosuppressive properties of cyclosporin A have been applied successfully to prevent the rejection of transplanted organs both in animals and humans. Clinically, it has been used in the management of transplanted kidneys, hearts, lungs, livers and, to some degree, pancreases and bone marrow. It is also finding some application in the control of various autoimmune conditions. The clinical use of cyclosporin A is still in an early phase and several aspects have not been defined optimally. The most common and troublesome side-effect is nephrotoxicity. Other adverse effects include hirsutism, gum hypertrophy and mild psychiatric disturbances as well as involvement of the gastrointestinal tract, liver and central nervous system.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3526101     DOI: 10.5694/j.1326-5377.1986.tb113775.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Chemical mutagenesis and high throughput media optimization in Tolypocladium inflatum MTCC-3538 leads to enhanced production of cyclosporine A.

Authors:  Vidushi Abrol; Manoj Kushwaha; Sharada Mallubhotla; Sundeep Jaglan
Journal:  3 Biotech       Date:  2022-07-05       Impact factor: 2.893

2.  Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation.

Authors:  Michael Choi; Can-Lan Sun; Seira Kurian; Andrea Carter; Liton Francisco; Stephen J Forman; Smita Bhatia
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.